Quantum Leap Healthcare Collaborative
search

"Separating contenders from
pretenders in breast cancer"

-- ASCO Post

"Blazes a trail in breast cancer"

-- Nature Biotechnology

"A glimpse into the future of
phase II drug development?"

-- NEJM
Close
Close
I-SPY Email List Sign-up
I-SPY  PATIENT INFORMATION SITE. Visit: www.ispypatient.org
Albain KS, Yau C, Petricoin EF, et al.
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
.
Clin Cancer Res
30
:
729-740
2024
.
abstract
pdf
doi
Albain KS, Yau C, Petricoin EF, et al.
Neoadjuvant Trebananib plus Paclitaxel-based Chemotherapy for Stage II/III Breast Cancer in the Adaptively Randomized I-SPY2 Trial—Efficacy and Biomarker Discovery
. In 
 (Eds.), 
Clin Cancer Res
30
(
); pp.
729-740
2024
.
abstract
pdf
link
Kyalwazi B, Yau C, Campbell MJ, et al.
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer
.
JAMA Network Open
6
:
e2349646
2023
.
abstract
pdf
doi
Kyalwazi B, Yau C, Campbell MJ, et al.
Race, Gene Expression Signatures, and Clinical Outcomes of Patients With High-Risk Early Breast Cancer
. In 
 (Eds.), 
JAMA Network Open
6
(
); pp.
e2349646
2023
.
abstract
pdf
link
Gallagher RI, Wulfkuhle J, Wolf DM, et al.
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial
.
Cell Rep Med
Published online 2023:101312
:
2023
.
abstract
pdf
doi
Gallagher RI, Wulfkuhle J, Wolf DM, et al.
Protein signaling and drug target activation signatures to guide therapy prioritization: Therapeutic resistance and sensitivity in the I-SPY 2 Trial
. In 
 (Eds.), 
Cell Rep Med
Published online 2023:101312
(
); pp.
2023
.
abstract
pdf
link

Featured News

What is I-SPY?

The I-SPY series of trials are changing the way new treatments are developed for breast cancer, helping make available new, better and more personalized treatments, faster. At the heart of the I-SPY program is the ground-breaking I-SPY 2 platform trial for neoadjuvant treatment of locally advanced breast cancer.

>2500
patients enrolled
25
agents completed
evaluation since 2010
3
agents received
accelerated approval
Find out more

World-class science requires world-class scientists

Meet some of our team

I-SPY is supported by:

I-SPY Sponsor:
Quantum Leap Healthcare Collaborative